文献速递肥胖与代谢综合征糖尿病

儿童青少年肥胖中空腹GLP-1水平升高的解读:是敌是友?

Elevation of Fasting GLP-1 Levels in Child and Adolescent Obesity: Friend or Foe?
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

本文是针对Stinson等横断面研究的评论,该研究纳入4000余名儿童青少年,发现超重/肥胖者空腹GLP-1升高并与心脏代谢危险因素相关。评论探讨了IL-6诱导GLP-1分泌、胰岛素抵抗代偿及脂质生成等可能机制,并强调生理与药理水平GLP-1效应不同,需进一步实验验证其临床意义。

要点

  • 儿童青少年超重/肥胖者空腹GLP-1升高,并与心脏代谢危险因素相关。
  • IL-6刺激胰腺α细胞分泌GLP-1可能参与β细胞代偿及脂质生成。
  • 生理与药理水平GLP-1效应不同,空腹GLP-1升高的临床意义尚待明确。

核心结论

  • Stinson等研究显示儿童青少年超重/肥胖者空腹GLP-1升高并与心脏代谢危险因素相关,但其与人类疾病和健康的相关性需进一步实验阐明。

研究设计与样本

  • 本文为针对Stinson等横断面研究的评论,该研究纳入超过4000名儿童青少年。

主要发现

  • 超重/肥胖儿童青少年空腹GLP-1较高,且与心脏代谢危险因素相关。
  • 炎症细胞因子IL-6可刺激胰腺α细胞分泌GLP-1,可能参与β细胞储备扩张以代偿胰岛素抵抗加重。
  • GLP-1分泌增加促胰岛素分泌,增强肝脏脂质生成并刺激脂肪生成,可能与空腹GLP-1与体脂百分比、甘油三酯和丙氨酸氨基转移酶的相关性有关。
  • GLP-1水平自然升高可能对抗体重增加以维持体重。

临床怎么用

  • 临床需注意GLP-1在生理水平与药理水平(如GLP-1受体激动剂、DPP-4抑制剂)的生物学效应不同。
  • 儿童青少年肥胖中空腹GLP-1升高与心脏代谢风险相关,但其临床解读需谨慎,尚不能作为干预依据。

局限性

  • Stinson研究为横断面设计,无法确立因果关系。
  • 空腹GLP-1升高与心脏代谢风险相关的机制尚需额外实验验证。
  • 生理与药理水平GLP-1效应不同,空腹GLP-1升高的临床相关性尚未完全明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Glucagon-like peptide-1 (GLP-1) receptor agonists have been gaining much attention as a therapeutic approach to type 2 diabetes and obesity. Stinson et al recently reported that fasting GLP-1 is higher in children and adolescents with overweight/obesity and that it associates with cardiometabolic risk factors in a cross-sectional study comprising more than 4000 subjects. Obvious questions include why fasting GLP-1 is significantly increased in children and adolescents with overweight/obesity and why this is correlated with cardiometabolic risks. It has been shown that the inflammatory cytokine interleukin-6 (IL-6) stimulates GLP-1 secretion from pancreatic α-cells. IL-6-induced GLP-1 secretion could therefore play a role in expanding the β-cell reservoir in compensation for increased insulin needs due to exacerbation of insulin resistance. On the other hand, augmented GLP-1 secretion leads to increased insulin secretion, thereby enhancing hepatic lipogenesis and stimulating adipogenesis, which might underlie the associations of fasting GLP-1 with % body fat, triglycerides, and alanine aminotransferase. It is also possible that GLP-1 levels are naturally increased to oppose body weight gain to maintain body weight. However, it is important to note the differing biological effects of GLP-1 at physiological and pharmacological levels, which are evident in body weight reduction by GLP-1 receptor agonists and DPP-4 inhibitors. The Stinson study clearly demonstrated that fasting GLP-1 associates with overweight/obesity and cardiometabolic risk factors in children and adolescents. However, additional experiments need to be carried out to fully understand the relevance of these observations to human disease and health.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Kubota S, Yabe D. Elevation of Fasting GLP-1 Levels in Child and Adolescent Obesity: Friend or Foe? J Clin Endocrinol Metab. 2021. PMID: 33950185. doi:10.1210/clinem/dgab301

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。